US 12,344,904 B2
Biomarkers and uses thereof
Flavia Huygens, Westlake (AU)
Assigned to Microbio Pty Ltd, Westlake (AU)
Filed by Microbio Pty Ltd, Westlake (AU)
Filed on Jul. 20, 2023, as Appl. No. 18/355,932.
Application 18/355,932 is a division of application No. 16/614,697, granted, now 11,739,389, previously published as PCT/AU2018/050471, filed on May 17, 2018.
Claims priority of application No. 2017901846 (AU), filed on May 17, 2017.
Prior Publication US 2024/0141443 A1, May 2, 2024
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/686 (2018.01); C12Q 1/689 (2018.01); C12Q 1/6895 (2018.01)
CPC C12Q 1/689 (2013.01) [C12Q 1/686 (2013.01); C12Q 1/6895 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/156 (2013.01)] 8 Claims
 
1. A method of identifying a bacterial species present in a sample, said method comprising analysing at least a portion of a bacterial 16S rRNA gene from the sample for the presence or absence of at least one single nucleotide polymorphism (SNP),
wherein analysing at least a portion of the bacterial 16S rRNA gene comprises:
a) amplifying the bacterial 16S rRNA gene with oligonucleotide primers comprising SEQ ID Nos: 56 and 57 to produce a DNA amplification product comprising the at least one SNP, and
b) using high-resolution melt analysis to analyse the DNA amplification product, thereby identifying the bacterial species;
wherein the at least one SNP is at a position corresponding to at least one of positions 737, 755, 762, and 776 of the 16S rRNA gene set forth in SEQ ID NO: 1;
the bacterial species is selected from the group consisting of Bacillus anthracis, Clostridium botulinum type A, Clostridium botulinum type B, Clostridium botulinum type C, Clostridium botulinum type D, Clostridium botulinum type G, Yersinia pestis, Francisella tularensis, Vibrio cholerae and Burkholderia pseudomallei; and
the sample is selected from the group consisting of: hair, skin, nails, biological tissue, sputum, saliva, cerebrospinal fluid, urine and blood.